Clinical trials: SARS Pneumonia
COVID, Corona Virus Infection
Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19
The most severe manifestations of COVID-19 include respiratory failure, coagulation problems, and death. Inflammation and blood clotting are believed to play an important role in these manifestations.
- Conditions
- COVID, Corona Virus Infection, Covid-19, SARS-CoV-2 Infection
- Trial name
- DICER (NCT04391179)
- Testing
- Dipyridamole 100 Milligram(mg)
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- University of Michigan
COVID-19
Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)
The purpose of this study is to assess the efficacy and safety of prazosin to prevent cytokine storm syndrome and severe complications in hospitalized patients with Coronavirus disease 2019 (COVID-19).
- Trial name
- PREVENT (NCT04365257)
- Testing
- Prazosin, Standard of care
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
Healthy Participants
A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).
The purpose of the study is to learn about the safety and effects of a combined vaccine for RSV and COVID-19 when given with a seasonal flu vaccine or when given alone.
- Trial name
- NCT05886777
- Testing
- Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF
- Where
- 37 sites in United States
- Volunteers
- 1,142 people, healthy volunteers welcome
- Sponsor
- Pfizer
Covid19
RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers
This is a first-in-human, open label, single dose, dose-escalation phase 1 study to evaluate the safety and pharmacokinetics of a combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the…
- Trial name
- RU (NCT04700163)
- Testing
- C144-LS and C-135-LS
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
COVID-19, SARS-CoV-2
Study of Sargramostim in Patients With COVID-19
The purpose of this research is to find out if a drug (sargramostim) also known as Leukine® could help patient recover faster from COVID-19.
- Trial name
- iLeukPulm (NCT04411680)
- Testing
- Sargramostim, Standard of care
- Where
- 11 sites in United States
- Volunteers
- 123 people
- Sponsor
- Partner Therapeutics, Inc.
SARS-CoV-2 Infection
To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects
This is a Phase I study that randomized, double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to evaluate Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects.
- Trial name
- NCT04525079
- Testing
- CT-P59
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Celltrion
SARS-CoV-2
PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19
This study is an adaptive, randomized, double blind, platform trial evaluating promising investigational products (IP) for safety and efficacy as early outpatient treatment and post-exposure prophylaxis for Severe Acute…
- Trial name
- PROTECT-APT 1 (NCT05954286)
- Testing
- Upamostat
- Where
- 6 sites in United States, South Africa and 2 more
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
COVID-19, SARS-CoV-2
Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
Prevention of COVID-19 caused by SARS-CoV-2.
- Trial name
- NCT05477186
- Testing
- CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg)
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Coronavirus Disease 2019 (COVID-19)
Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
The purpose of this study is to assess whether convalescent plasma therapy is associated with reduced 30-day all-cause mortality in a population of Veteran inpatients with non-severe coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04545047
- Testing
- COVID-19 convalescent plasma
- Where
- 2 sites in United States
- Volunteers
- 5,044 people
- Sponsor
- VA Office of Research and Development